Prasad Under Fire Again As Moderna RTF Draws Industry Backlash

By Jessica Karins / February 12, 2026 at 4:07 PM

FDA biologics center director Vinay Prasad is again under fire from industry after refusing to review Moderna’s application for its mRNA influenza vaccine, with the Wall Street Journal slamming Prasad in an editorial for creating a toxic environment that stifles innovation.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.